Cannabis Metabolomics Associations Used Baseline and Placebo Differences Rather Than a Standalone Blood Value
The metabolomics study related cannabis effects to changes from baseline and differences from placebo. Those analyses did not directly validate classification from one isolated post-use serum sample.
The investigators constructed different change measures
For attentional lapses and subjective high, they subtracted the participant’s placebo-condition score from the cannabis-condition score. For metabolomics, they calculated changes from pre-dose baseline. Their models then examined associations between these defined changes, with additional participant characteristics included as predictors.
A change score needs a reference
An absolute concentration combines the person’s starting value with subsequent influences. A within-person change addresses a different question. If a real-world test lacks a pre-use sample or placebo comparison, it cannot simply reproduce the study’s calculations. The authors explicitly identify standalone sampling and full time-course validation as future research needs.
Association is a step toward validation
The controlled design helps investigate candidate relationships under known exposure conditions. It does not establish a ready-to-use decision rule or show that a later recovered sample is an interchangeable baseline. That substitution was discussed as a possibility requiring study. For interpretation, specify which reference values supported the association and which would be unavailable in the proposed application. This prevents a controlled change analysis from being presented as an already validated single-sample impairment assay.
Related analysis: the study’s broader findings and limitations.
